CLAIMS

1.

A pharmaceutical composition comprising at least one inhibitor of lipases and at least one fatty acid ester of polyols, characterized in that the fatty acid ester has a melting point above the body temperature and the polyols are chosen from the group consisting of glycerol, sugars, sugar derivatives and mixtures thereof.

2.	The pharmaceutical composition according to claim 1, wherein the polyols are chosen, independently from each other, from the group consisting of sucrose, glycerol, and sugar alcohols.

3.	The pharmaceutical composition according to claim 1 or 2, wherein the polyol is glycerol.

4.	The pharmaceutical composition according to any of claims 1 to 3, wherein the fatty acid ester is a glyceride ester and is chosen from the group consisting of one or more triglycerides, one or more monoglycerides, one or more phospholipids and mixtures thereof.

5.	The pharmaceutical composition according to any of claims 1 to 4, wherein the fatty acid moieties in the fatty acid ester of the polyol have, independently from each other, twelve or more carbon atoms and the fatty acid moieties in the fatty acid ester of the polyol are saturated.

6.	The pharmaceutical composition according to claim D, wherein the fatty acid moieties in the fatty acid ester of the polyol have, independently from each other, twelve to twenty carbon atoms.

7.	The pharmaceutical composition according to any of claims 4 to 6, wherein the triglycerides are chosen from the group consisting of trilaurin, trimyristin, tripalmitin, tristearin and mixtures thereof.

8.	The pharmaceutical composition according to claim 7, wherein the triglyceride is trimyristin or trilaurin or mixtures thereof.

9.	The pharmaceutical composition according to any of claims 4 to 6, wherein the monoglycerides are chosen from the group consisting of monocaprin, monolaurin, monomyristin, monopalmitin and mixtures thereof.

10.	The pharmaceutical composition according to any of claims 4 to 6, wherein the phospholipid is a lecithin.

11.	The pharmaceutical composition according to claim 10, wherein the phospholipid is a non, partially or fully hydrogenated lecithin and mixtures thereof.

12.	The pharmaceutical composition according to claim 10 or 11, wherein the phospholipids are chosen from the group consisting of natural lecithin, synthetic lecithin, sojalecithin, egglecithin, synthetic dipalmitoyllecithin, partially or fully. hydrogenated lecithin and mixtures thereof.

13.	The pharmaceutical composition according to any of claims 1 to 12, wherein the fatty acid ester of polyols is present in an amount varying between 0.5 % and 90 % of the total weight of the composition.

14.	The pharmaceutical composition according to any of claims 1 to 13, further comprising at least one pharmaceutically acceptable excipient.

15.

The pharmaceutical composition according to claim 14, wherein the excipient is selected from the group consisting of carbohydrates, starch and/or its derivatives, maltodextrines, cellulose, cellulose derivatives, sugars, fillers, disintegrants, effervescents, antioxidants, anionic surfactants, nonionic surfactants and mixtures thereof.

16.	The pharmaceutical composition according to claim 15, wherein the surfactant is selected from the group consisting of sodium dodecylsulfate, fatty acid salts, polyoxyethylene alkyl esters and polyoxyethylene alkyl ethers and mixtures thereof.

17.	The pharmaceutical composition according to any of claims 14 to 16, comprising an excipient selected from the group consisting of glucose, lactose, sorbitol, maltodextrin, talcum, magnesium stearate, mannitol, sodium bicarbonate, Crospovidone, glycofurol, tartaric acid and mixtures thereof.

18.	The pharmaceutical composition according to any of claims 1 to 17, wherein the inhibitor of lipases is an inhibitor of gastrointestinal lipases.

19.	The pharmaceutical composition according to claim 18, wherein the inhibitor of gastrointestinal lipases is orlistat.

20.	The pharmaceutical composition according to any of claims 1 to 19, wherein the lipase inhibitor is present in an amount varying from 1 to 50% of the total weight of the composition.

21.	The pharmaceutical composition according to claim 20, wherein the lipase inhibitor is present in an amount varying from 5 to 30'Yo of the total weight of the composition.

22.

The pharmaceutical composition according to any of claims 1 to 21, wherein a) 1 to 50% of the total weight of the composition is at least one lipase inhibitor; b) 0.5 to 90% of the total weight of the composition is at least one fatty acid ester of polyols; and optionally c) the composition comprises one or more pharmaceutically acceptable 'excipient (s).

23.

A process for preparing a pharmaceutical composition according to any one of claim 1 to 22, comprising mixing at least one inhibitor of lipases with at least one fatty acid ester of polyols, wherein the fatty acid ester of polyols has a melting point above the body temperature and the polyols are chosen from the group consisting of glycerol, sugars, sugar derivatives and mixtures thereof.

24.	Use of a pharmaceutical composition as defined in any one of claim 1 to 22 for controlling or preventing obesity.

25.	A method for controlling or preventing obesity comprising the step of administering to a patient a pharmaceutical composition as defined in any one of claims 1 to 22.

26.	Use of a composition as defined in any of claims 1 to 22 for the preparation of a medicament for the prevention and treatment of obesity.

27.	The invention as hereinbefore described.